Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Review uri icon

Overview

abstract

  • Research into the role of the human epidermal receptor growth factor receptor 1/epidermal growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of anticancer drugs. One such agent, erlotinib (Tarceva), is a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. Erlotinib has demonstrated the clinical activity in a variety of solid tumors, and has recently demonstrated improvements in survival in large Phase III trials, in non-small-cell lung cancer and pancreatic cancer.

publication date

  • August 1, 2005

Research

keywords

  • Carcinoma, Non-Small-Cell Lung
  • ErbB Receptors
  • Lung Neoplasms
  • Pancreatic Neoplasms
  • Protein Kinase Inhibitors
  • Quinazolines

Identity

Scopus Document Identifier

  • 33744503415

PubMed ID

  • 16556021

Additional Document Info

volume

  • 1

issue

  • 4